Genprex(US:GNPX) Prnewswire·2025-02-13 13:15Core Insights - Genprex, Inc. announced significant findings regarding NPRL2 gene therapy's effectiveness in treating anti-PD1 resistant non-small cell lung cancer (NSCLC) using a non-viral delivery system [1][2][3] - The study demonstrated that NPRL2 gene therapy alone produced a dramatic antitumor effect, while pembrolizumab (Keytruda®) was ineffective on its own [2][3] - The Oncoprex® Delivery System, which utilizes lipid nanoparticles, allows for the intravenous delivery of tumor suppressor genes, minimizing toxicity risks associated with viral systems [1][4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its non-viral Oncoprex® Delivery System [5][6] - The company's lead product, Reqorsa® Gene Therapy, is currently being evaluated in clinical trials for NSCLC and small cell lung cancer (SCLC) [5][6] - Genprex's oncology programs have received Fast Track Designation from the FDA, and the SCLC program has received Orphan Drug Designation [6] Research Findings - The NPRL2 gene therapy showed greater antitumor effects in humanized mice compared to non-humanized NSG mice, indicating the role of the immune system in its efficacy [3] - The therapy targets KRAS/STK11 mutant tumors, which are known to be resistant to conventional treatments, suggesting potential applicability to approximately 30% of NSCLCs with KRAS mutations [3]